Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)

Helena A. Yu, Sarah B. Goldberg, Xiuning Le, Zofia Piotrowska, Jonathan W. Goldman, Adrianus J. De Langen, Isamu Okamoto, Byoung Chul Cho, Paul Smith, Ilhem Mensi, Helen Ambrose, Silvija Kraljevic, Julie Maidment, Juliann Chmielecki, Xiaocheng Li-Sucholeiki, Gail Doughton, Gargi Patel, Phil Jewsbury, Phil Szekeres, Jonathan W. Riess

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)'. Together they form a unique fingerprint.

Medicine & Life Sciences